Salute e Benessere

SciBase: Interim report

The third quarter in figures The third quarter in figures The first nine months in figures Important events during the quarter Important events after the end of the period This information is information that SciBase Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08.30 CET on7 November 2025. This report has been...
PR Newswire
07/11/2025

The Board of Directors in SciBase resolves on an offer to repurchase outstanding…

Summary of the TO 2 Offer Summary of the TO 2 Offer Summary of the Rights Issue "SciBase is developing well with a growing and profitable operation inGermanyand rapid growth in the US. In addition to our strong performance within melanoma diagnostics, we are accelerating our activities in other skin diseases together with Castle Biosciences. The upcoming Rights Issue will provide runway for continued growth that will set us on a course towards profitability. There is a strong...
PR Newswire
07/11/2025

SciBase and Castle Biosciences expand collaboration and license agreement and…

"Our collaboration with Castle Biosciences is moving ahead at full speed," said Pia Renaudin, CEO of SciBase. "With this loan, we secure the resources needed to smoothly ramp up production and maintain uninterrupted growth. We expect the resulting improvements in product margins will create value across all markets and indications. This collaboration will also help us accelerate the adoption of Nevisense in skin barrier health and continue driving strong sales growth in skin…
PR Newswire
07/11/2025

Memo Therapeutics AG Presents Long Term Follow-Up Data from its Phase II SAFE…

PRESS RELEASE Memo Therapeutics AG Presents Long Term Follow-Up Data from its Phase II SAFE KIDNEY Trial of Potravitug and Real World Data on the Challenges and Resource Utilization of Managing Kidney Transplant Recipients at ASN Kidney Week MeetingLong term follow-up data shows a sustained and improved (vs. week 20) benefit of potravitug on BK polyomavirus viral load in kidney transplant recipients at week 38 (study end)Potravitug was well tolerated, with no treatment related...
Nasdaq GlobeNewswire
07/11/2025

Coway Announces Financial Results for Q3 FY2025

Coway's reported earnings are as follows: Coway's reported earnings are as follows: Coway's cumulative revenue for 2025 has now reachedKRW 3,688.2 billion(+15.8% YoY), with an operating profit ofKRW 697.0 billion(+13.9%). Within the domestic market, Coway achieved a third-quarter revenue ofKRW 740.2 billion, a 12% increase when compared with the same period last year. This strong performance was driven by robust sales of the new Icon Ice Water Purifier series, which features...
PR Newswire
07/11/2025

Endometrial Cancer Market Poised for Expansion Throughout Forecast Period…

Endometrial Cancer Market Summary Endometrial Cancer Market Summary Discover the endometrial cancer new treatment @New Treatments for Endometrial Cancer Key Factors Driving the Growth of the Endometrial Cancer Market Rising incidence driven by demographic and lifestyle factors Ageing populations plus increases in obesity and metabolic conditions are raising endometrial cancer incidence in many regions — a larger patient pool increases demand for diagnostics, treatment...
PR Newswire
06/11/2025

Combined General Meeting of November 27, 2025 - Availability of the preparatory…

Daix (France), New York City (New York, United States), November 6, 2025– Inventiva (Euronext Paris and Nasdaq : IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the availability of the preparatory documents for the Combined General Meeting of November 27, 2025.Shareholders are invited to participate in the...
Nasdaq GlobeNewswire
06/11/2025

Alkermes to Participate in Two Upcoming Investor Conferences

Jefferies Global Healthcare Conference in LondonDate/Time:Wednesday, Nov. 19, 2025 at 11:30 a.m. ET (4:30 p.m. GMT) Jefferies Global Healthcare Conference inLondonDate/Time:Wednesday, Nov. 19, 2025at11:30 a.m. ET( 4:30 p.m. GMT ) The live webcasts may be accessed under the Investors tab onwww.alkermes.comand will be archived for 14 days. About Alkermes plc Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that...
PR Newswire
06/11/2025

Statement of total voting rights and shares forming the company’s share capital…

Article R. 22-10-23 of the French Commercial Code Market : Euronext Paris ISIN code / Mnemo : FR0013233012 / IVA Web site : www .inventivapharma.com DateNumber of Shares Outstanding Total voting rights,gross(1) Total voting rights,net(2)October 20 th, 2025145 951 274158 653 570158 594 019(1) The total number of gross (or “theoretical”) voting rights is used as the basis for...
Nasdaq GlobeNewswire
06/11/2025

Novo Nordisk's CagriSema was associated with significant reduction in blood…

"We're very excited by the results of these analyses of CagriSema, which show promising results of combining cagrilintide with the proven significant effects of semaglutide on CV health," said Martin Holst Lange, chief scientific officer and executive vice president of Research & Development at Novo Nordisk. "People living with obesity have treatment goals that often include both losing weight and improving overall health. That's why we continue to explore new therapies that…
PR Newswire
06/11/2025

Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to…

Obesity medicines coverage in U.S. Medicare Part D via a pilot programme, starting during 2026Introduction of lower prices for Novo Nordisk’s semaglutide medicines in U.S. Medicare Part D and Medicaid and in direct-to-patients cash channelNovo Nordisk currently expects an estimated negative low single-digit impact on global sales growth in 2026Bagsværd, Denmark, 6 November 2025– Today it was announced that Novo Nordisk has agreed with the U.S. Administration to lower drug prices...
Nasdaq GlobeNewswire
06/11/2025

EssilorLuxottica expands its myopia management platform with Essilor Stellest…

EssilorLuxottica expands its myopia management platform with Essilor Stellest 2.0 lenses, smart glasses and an innovative pre-myopia solutionParis, France (6 November 2025)– EssilorLuxottica today announced the evolution of its Essilor Stellest platform at the China International Import Expo (CIIE) in Shanghai. Building on the Group’s forty-five years of research and innovation in myopia management, the enhanced Essilor Stellest portfolio reinforces EssilorLuxottica’s commitment to...
Nasdaq GlobeNewswire
06/11/2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 44 - 2025

Aggregated presentation by day and by marketStatement of transactions in own shares from October 27 thto October 31 st2025 Name of the issueIdentity code of the issuer(Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1127/10/2025...
Nasdaq GlobeNewswire
06/11/2025

Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data…

Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025Compelling kidney function data from VIVIAD Phase 2b study presented in late-breaking poster at ASN kidney week, the world’s premier nephrology meetingVIVIAD analyses continue to support varoglutamstat’s potential in kidney disease, and consistently provide further evidence for a beneficial impact on kidney function based on its proposed mechanism...
Nasdaq GlobeNewswire
06/11/2025

Embla Medical Expands Support for Ukrainian Amputees with New Kyiv Clinic and…

The initiative responds to an unprecedented national need. Since 2022, the Ukrainian government estimates that more than 50,000 people have suffered amputations due to war-related trauma, with numbers continuing to rise. Embla Medical has been actively supporting the development of Ukraine's prosthetic sector over the past several years, and the new clinic and initiative further strengthen that commitment. The initiative responds to an unprecedented national need. Since 2022, the Ukrainian...
PR Newswire
06/11/2025

Australian Sleep Tech Company Launches a Smart Ring to Transform Sleep & Health…

Why another Ring? While smart rings are rapidly becoming the future of health tracking, offering greater accuracy and more comfort than wrist-based devices, the company is looking far beyond just monitoring. With the retimer Ring, RTPL takes the next step by leveraging its legacy, and the progress in sensor technology and AI, to offer sleep, health and activity tracking, with more exciting features planned for circadian health, apnea and insomnia. "retimer Ring isn't just...
PR Newswire
06/11/2025

Growth in revenue and operating profit

Trading statement for Q1 2025/26 (1 July - 30 September 2025) Growth in revenue and operating profit Revenue was up by 8% in Q1 2025/26 (11% at constant exchange rates) to DKK 124.6 million from DKK 115.6 million in the year-earlier period. The Q1 performance reflected continued growth in sales of instruments, consumables and services. Moreover, ChemoMetec is experiencing growing interest in its technology, not least the XcytoMatic platform, and this trend is expected to continue,...
Nasdaq GlobeNewswire
06/11/2025

Genmab Announces Financial Results for the Nine Months of 2025

November 6, 2025 Copenhagen, Denmark;Interim Report for the Nine Months Ended September 30, 2025Highlights Announcement of Genmab’s proposed acquisition of Merus N.V. (Merus)Genmab revenue increased21% compared to the first nine months of 2024 , to $2,662 millionFDA granted BTD to Rina-S ®in advanced endometrial cancerEpcoritamab Phase 3 EPCORE ®FL-1 trial met dual primary endpoints of ORR and PFS, demonstrating statistically significant and...
Nasdaq GlobeNewswire
06/11/2025

Pharmacovigilance Market to Reach $26.2 billion, Globally, by 2034 at 12.3%…

Market Introduction Market Introduction The pharmacovigilance market encompasses a broad range of systems, services, and technologies dedicated to monitoring, detecting, assessing, and preventing adverse effects or any other drug-related problems throughout a pharmaceutical product's lifecycle. It plays a pivotal role in ensuring drug safety, regulatory compliance, and public health, and is integral to both clinical development and post-marketing surveillance. Pharmacovigilance activities...
PR Newswire
06/11/2025

Neurovascular Devices Market worth $7.22 billion in 2030 with 9.3% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=847 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=847 Browse in-depth TOC on "Neurovascular Devices Market" 150 - Tables 70 - Figures 300 - Pages By disease pathology,the global neurovascular devices market is divided into five main segments: cerebral aneurysms, ischemic strokes, carotid artery stenosis, arteriovenous malformations and fistulas, and other...
PR Newswire
06/11/2025

Global Telehealth Market Size to Exceed USD 156.3 Billion by 2035, Rising at…

Market Highlights Market Highlights Key Regional Markets Leading the Way The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.vantagemarketresearch.com/telehealth-market-1246/request-sample Free Sample Includes: Technological & Industry Momentum Why This Matters for Executives & Investors? The Telehealth market is emerging as one of the fastest-growing frontiers in healthcare digitization,...
PR Newswire
06/11/2025

Nitinotes Receives CE Mark Approval of EndoZip™, the First Fully Automated…

Obesity is one of the most urgent global health challenges, affecting more than 650 million adults worldwide. Current treatment pathways leave a significant gap between medical management such as GLP-1 therapy and invasive bariatric surgery. ESG is emerging as a minimally invasive alternative, addressing patients with obesity (BMI 30–40 kg/m²) who have not achieved success with conservative measures such as diet, exercise, or medication. Obesity is one of the most urgent global health...
PR Newswire
06/11/2025

Consortium consisting of Nordic Capital and Permira announces preliminary result…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONCOPENHAGEN, Denmark, 6 November, 2025– With reference to company announcements dated 26 August 2025 (no. 24/2025), 29 September 2025 (no. 27/2025), 15 October 2025 (no. 31/2025), and 21 October 2025 (no. 33/2025) regarding the all-cash voluntary board-recommended public takeover offer to...
Nasdaq GlobeNewswire
06/11/2025

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a…

REYKJAVIK, ICELAND and LONDON, UK (November 06, 2025)— Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted...
Nasdaq GlobeNewswire
06/11/2025
Altri  Comunicati